NCT02978222.

Trial name or title	A randomized multicenter phase II trial to evaluate the safety, efficacy and immunogenicity of vaccination with folate receptor alpha peptides with GM‐CSF versus GM‐CSF alone in patients with platinum sensitive ovarian cancer and a response or stable disease to platinum therapy
Methods	Multi‐centre double‐blind controlled randomised phase II study
Participants	120 participants with platinum‐sensitive ovarian cancer
Interventions	FRα peptide vaccine with GM‐CSF or GM‐CSF alone
Outcomes	Survival Clinical response
Starting date	November 2016
Contact information
Notes	Recruting, April 2018